Year archive

Enlivex Therapeutics Ltd. — 2025 filings

All 63 regulatory filings released by Enlivex Therapeutics Ltd. (ENLV) in 2025, sourced directly from the official regulator.

63 Filings

2025 Period

2025 filings (63)

Filing	Released	Lang
Other Report or Announcement Transaction in Own Shares	2025-12-24	English
Other Report or Announcement Report Publication Announcement	2025-12-24	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2025-12-19	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2025-12-19	English
Immediate Report of Meeting AGM Information	2025-12-19	English
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development Regulatory Filings	2025-12-04	English
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development Regulatory Filings	2025-12-04	English
Immediate Report Capital/Financing Update	2025-11-26	English
Immediate Report Regulatory Filings	2025-11-26	English
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Capital/Financing Update	2025-11-24	English
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Report Publication Announcement	2025-11-24	English
Renewal of shelf prospects effective of May 12, 2025 Share Issue/Capital Change	2025-11-24	English
Renewal of shelf prospects effective of May 12, 2025 Report Publication Announcement	2025-11-24	English
The company's announcement regarding $212,000,000 Private Placement was published abroad Share Issue/Capital Change	2025-11-24	English
Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis Investor Presentation	2025-11-24	English
Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2025-11-24	English
Results of a meeting held on November 7, 2025 Declaration of Voting Results & Voting Rights Announcements	2025-11-18	English
Results of a meeting held on November 7, 2025 Regulatory Filings	2025-11-18	English
Report of Periodic or Interim Report Interim / Quarterly Report 9M 2025	2025-11-15	English
Report of Periodic or Interim Report Report Publication Announcement	2025-11-15	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2025-11-11	English
Immediate Report of Meeting AGM Information	2025-11-11	English
Annual Meeting will be reconvened on Monday, November 17, 2025, beginning at 7:00 p.m. Israel time AGM Information	2025-11-11	English
Annual Meeting will be reconvened on Monday, November 17, 2025, beginning at 7:00 p.m. Israel time Regulatory Filings	2025-11-11	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2025-09-26	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2025-09-26	English
Immediate Report of Meeting AGM Information	2025-09-26	English
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results Regulatory Filings	2025-09-11	English
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results Regulatory Filings	2025-09-11	English
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Regulatory Filings	2025-09-09	English
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Regulatory Filings	2025-09-09	English
Presentation- PHASE IIA TOPLINE RESULTS Investor Presentation	2025-08-18	English
Presentation- PHASE IIA TOPLINE RESULTS Regulatory Filings	2025-08-18	English
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis Regulatory Filings	2025-08-18	English
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis Regulatory Filings	2025-08-18	English
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar Regulatory Filings	2025-08-14	English
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar Regulatory Filings	2025-08-14	English
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data Regulatory Filings	2025-07-28	English
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data Report Publication Announcement	2025-07-28	English
Financial statements as of a March 31, 2025 Interim / Quarterly Report Q1 2025	2025-05-31	English
Financial statements as of a March 31, 2025 Regulatory Filings	2025-05-31	English
Renewal of ATM plan Capital/Financing Update	2025-05-14	English
Renewal of ATM plan Report Publication Announcement	2025-05-14	English
FORM F-3-prospectus in one or more offerings Capital/Financing Update	2025-05-03	English
FORM F-3-prospectus in one or more offerings Report Publication Announcement	2025-05-03	English
20F For the fiscal year ended December 31, 2024 Annual Report FY 2024	2025-05-01	English
20F For the fiscal year ended December 31, 2024 Report Publication Announcement	2025-05-01	English
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress Regulatory Filings	2025-04-23	English
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress Report Publication Announcement	2025-04-23	English
Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis Regulatory Filings	2025-04-21	English
Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis Report Publication Announcement	2025-04-21	English
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Regulatory Filings	2025-04-03	English
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Report Publication Announcement	2025-04-03	English
FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 Regulatory Filings	2025-04-01	English
FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 Report Publication Announcement	2025-04-01	English
Form 6-K- Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Regulatory Filings	2025-03-17	English
Form 6-K- Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Report Publication Announcement	2025-03-17	English
Investor Webinar on March 5, 2025, at 11:00 a.m. ET to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis Regulatory Filings	2025-03-05	English
Investor Webinar on March 5, 2025, at 11:00 a.m. ET to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis Report Publication Announcement	2025-03-05	English
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2025-03-03	English
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis Report Publication Announcement	2025-03-03	English
Enlivex Issues Urgent Statement on Fraudulent News Dissemination Regulatory Filings	2025-02-18	English
Enlivex Issues Urgent Statement on Fraudulent News Dissemination Report Publication Announcement	2025-02-18	English

Filings by year

2026 45 filings
2025 63 filings
2024 69 filings
2023 55 filings
2022 62 filings
2021 73 filings
2020 78 filings
2019 40 filings